| Objective:1.Clinical research Objectively evaluate the clinical efficacy of Yiqi Guben Capsules in the treatment of children with asthma in remission,and provide a scientific basis for the clinical use of Yiqi Guben Capsules in asthma.2.Experimental research Taking the role of ILC2 s cells in airway inflammation of allergic asthma as the starting point,to explore the inhibitory effect and specific mechanism of Yiqi Guben Capsule on ILC2 s cells.Method:1.Clinical research100 asthmatic children in remission stage were divided into test group(60 cases)and control group(40 cases).The test group was treated with Yiqi Guben capsule and the control group was treated with non traditional Chinese medicine.The treatment course of the two groups was one month.Three months and six months after the end of treatment,the patients were followed up once,to objectively evaluate the clinical efficacy of Yiqi Guben Capsules in improving asthma control efficiency and asthma control score,reducing the number of asthma attacks and improving respiratory tract infection.2.Experimental research2.1 Thirty mice were randomly divided into Control group,Model group,Dexamethasone group,YQGBC low dose group and YQGBC high dose group,with 6 mice in each group.2.2 The mice were sensitized by intraperitoneal injection of a mixture of OVA and AL(OH)3,and stimulated by ultrasonic nebulization with OVA to establish a mouse model of allergic asthma.2.3 The lung tissues of each group were taken for HE staining to observe the infiltration of inflammatory cells around the bronchioles.2.4 PAS staining was used to observe the proliferation of airway epithelial goblet cells and the secretion of mucus in the bronchial cavity in each group.2.5 The content of EOS and ILC2 s in BALF and lung tissue of mice in each group was detected by flow cytometry.2.6 Quantitative description of the percentage of IL-5+ILC2s and IL-13+ILC2s in lung tissue of each group by flow cytometry staining.2.7 ELISA and RT-PCR detection and analysis of IL-4,IL-5 and IL-13 content and m RNA expression levels in lung tissues of each group.2.8 Western Blot technique was used to analyze the m RNA and protein expressions of GATA3 and RORA in lung tissues of each group.2.9 Western Blot technique was used to analyze the protein expressions of p-IKK and p-NF-κB in lung tissues of each group.Results:1.Clinical research1.1 Asthma control rate: After the treatment,the total clinical effective rate of asthma control in the test group was 88%,and that in the control group was 80%.The test group was better than the control group(p<0.05).1.2 Number of asthma attacks: The number of asthma attacks in the test group was 1.5± 0.72 and 1.38 ± 0.49 respectively three months and six months after treatment,and 2.25 ±1.02 times in the first half year after treatment.The number of asthma attacks in the three months and six months after treatment was significantly lower than that in the first half year after treatment(p<0.05).The number of asthma attacks in the control group was 1.6 ± 0.62 and 1.75 ± 0.79 respectively three months and six months after the end of treatment,and2.27 ± 0.82 times in the first half of treatment.The number of asthma attacks in three months and six months after the end of treatment was significantly lower than that in the first half of treatment(p<0.05).The comparison between the two groups after half a year of treatment showed that the test group was better than the control group(p<0.05).1.3 Respiratory Infections: The number of respiratory tract infection episodes in the test group and the control group was significantly lower than that in the first half of the treatment(p<0.05).Compared with the second half of the treatment,the test group was better than that in the control group(p<0.05).The number of days of respiratory tract infection in the test group and the control group was significantly lower than that in the first half of the treatment(p<0.05).After half a year of treatment,the test group was better than the control group(p<0.05).Half a year after the treatment,the average monthly single disease grade of respiratory tract in the test group was lower than that in the first half of the treatment(p<0.05),and there was no significant difference in reducing the average monthly single disease grade of respiratory tract infection in the control group(p>0.05).After half a year of treatment,the test group was better than the control group(p<0.05).1.4 Follow-up efficiency: The effective rates of asthma follow-up in the test group three months and six months after the end of treatment were 95% and 96% respectively,and the effective rate of asthma at the end of treatment was 88%.There was no significant difference between three months after treatment and at the end of treatment(p>0.05),and there was significant difference between six months after treatment and at the end of treatment(p<0.05).The effective rates of asthma follow-up three months and six months after treatment in the control group were 80% and 75% respectively.At the end of treatment,the effective rate of asthma was 80%.There was no significant difference between three months and six months after treatment and at the end of treatment(p>0.05).The comparison between the two groups after half a year of treatment showed that the test group was better than the control group(p<0.05).1.5 Follow-up Asthma Control Score: The asthma control scores of the test group were24.98 ± 2.88 and 24.98 ± 2.76 three months and six months after the end of treatment,and24.77 ± 2.63 at the end of treatment.There was no significant difference between three months and six months after treatment and at the end of treatment(p>0.05).The asthma control scores of the control group were 24.05 ± 3.27 and 23.12 ± 4.30 three months and six months after the end of treatment,and 22.38 ± 4.81 at the end of treatment.There was significant difference between three months after treatment and at the end of treatment(p<0.05).There was no significant difference between half a year after treatment and at the end of treatment(p>0.05).After half a year of treatment,the test group was better than the control group(p<0.05).2.Experimental research2.1 After combined sensitization of OVA and AL(OH)3 and stimulation of OVA ultrasonic atomization,the mouse model of allergic asthma showed abnormal behaviors such as sneezing,nodding,breathing,shortness of breath and irritability.The above behaviors were improved after treatment with Yiqi Guben capsule and Dexamethasone.2.2 In the pathological staining of HE and PAS,the tracheal basement membrane of the asthma model group was thickened,the mucosa was shed,and there were a lot of inflammatory cells,goblet cells and mucins around the bronchi and alveoli.After treatment with Yiqi Guben capsules and Dexamethasone,inflammatory cell infiltration,goblet cell proliferation and mucus secretion around the trachea and alveoli were improved,the thickening of the basement membrane was alleviated to varying degrees,and the mucosal epithelium was relatively intact.2.3 The contents of EOS and ILC2 s cells in the lung and BALF of allergic asthma mice were higher than those in the control group.After treatment with Yiqi Guben capsules and Dexamethasone,the number of EOS and ILC2 s cells in the lung and BALF of mice were decreased.2.4 The percentages of IL-5+ILC2s and IL-13+ILC2s in the lungs of allergic asthma mice were higher than those in the control group.After treatment with Yiqi Guben capsule and Dexamethasone,the percentages of IL-5+ILC2s and IL-13+ILC2s were decreased.2.5 The secretion content of IL-4,IL-5 and IL-13 in the BALF of allergic asthma mice and the expression of m RNA in the lung were higher than those in the control group.IL-4,IL-5 and IL-13 secretion and m RNA expression in the lung were decreased.2.6 The m RNA and protein expressions of GATA3 and RORA in the lungs of allergic asthma mice were higher than those in the control group.After treatment with Dexamethasone and Yiqi Guben capsules,the m RNA and protein expressions of GATA3 and RORA in the lungs of mice were decreased.2.7 The protein expressions of p-IKK and p-NF-κB in the lungs of allergic asthma mice were higher than those in the control group.After treatment with Dexamethasone and Yiqi Guben capsules,the protein expressions of p-IKK and p-NF-κB in the lungs of mice were decreased.Conclusion:1.Yiqi Guben Capsule has a therapeutic effect on children’s asthma in remission period,can improve asthma control rate and asthma control score,reduce the number of asthma attacks,reduce the number of respiratory tract infections and the number of days of respiratory tract infections,lower the level of respiratory tract infections,and is safe and has no adverse reactions.2.Yiqi Guben capsule may inhibit IKK/NF-κB signal axis,reduce the m RNA and protein expression of GATA-3 and RORA,which regulate the development of ILC2 s cells,reduce the activated content of ILC2 s cell in allergic asthmatic mice,reduce the percentage of IL-5+ILC2s and IL-13+ILC2s in lung tissue,and the secreted content and m RNA expression of cytokines IL-4,IL-5 and IL-13,so as to play the role of anti asthmatic airway inflammation. |
PDF Full Text Request